Press What’s news at AbelsonTaylor Group
Select category
The Pros and Cons of Using AI in Developing Scientific Communications
AI is rapidly reshaping scientific communications — but speed and scale don’t replace judgment. In a July 7, 2025 MedAdNews article, AbelsonTaylor Group’s Colleen Loughney explores where AI meaningfully improves efficiency in medical writing and where human expertise remains non-negotiable. Drawing on two decades of experience at the intersection of clinical science, strategy, and regulation, she outlines the real opportunities, real risks, and the responsibility agencies have when patient safety and trust are on the line.
Read more: The Pros and Cons of Using AI in Developing Scientific Communications
https://www.pharmalive.com/the-pros-and-cons-of-using-ai-in-developing-scientific-communications/
Media Contact:
Recent Posts
The missing skill in the AI era isn’t prompting — It’s curiosity
“Curiosity is what builds judgment, and this is why AI is most powerful in the hands of curious people,” according...
In the News Read more The missing skill in the AI era isn’t prompting — It’s curiosityThe biggest barrier to AI adoption in healthcare isn’t regulation. It’s trust.
As AI adoption accelerates, trust may be the real differentiator. In MedAdNews, Janet Barker-Evans, Chief Creative Officer of AbelsonTaylor Group,...
In the News Read more The biggest barrier to AI adoption in healthcare isn’t regulation. It’s trust.From Insights to Action: The Bridge Between Strategy and Execution
“Having access to more information doesn’t automatically lead to better decisions—you need judgment,” says AbelsonTaylor Group’s Amy Restko, VP, Engagement...
In the News Read more From Insights to Action: The Bridge Between Strategy and ExecutionConnect with us
Find out what's top of mind for the people reimagining health and wellness advertising.